New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:17 EDTMRTXMirati Therapeutics price target raised to $27 from $20 at Brean Capital
Brean Capital raised its price target on Mirati Therapeutics as the company continues to move its pipeline forward, positive trials updates, and expectations for upfront payments and royalties from potential partnerships. Shares are Buy rated.
News For MRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
17:23 EDTMRTXMirati Therapeutics to update pipeline programs at 2015 ASCO
Mirati Therapeutics announced that the company will provide an update on its investigational targeted tyrosine kinase inhibitor candidates, MGCD265 and MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat, at the 2015 American Society of Clinical Oncology Annual Meeting to be held in Chicago from May 29-June 2, 2015. The updates on MGCD265 will be presented as part of the developmental therapeutics category. MGCD516 and mocetinostat will be presented as clinical trials in progress."We are pleased to participate in the 2015 ASCO Annual Meeting and present the progress we have made with each of Mirati's targeted oncology candidates," said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. "We look forward to providing new insights concerning the scientific basis and clinical utility of our lead candidate, MGCD265, for patients with non-small cell lung cancer who are diagnosed with MET- or Axl-driven tumors."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use